CABI contributes to paper focused on pre-emptive benefit-risk assessment of classical biological control agents
CABI has joined an international team of researchers to share their expertise as part of a new paper focused on guidelines and a framework to assess the feasibility of starting pre-emptive benefit-risk assessment of classical biological control agents (BCAs).